Why Kidney Care’s Biggest Investment Wave Hasn’t Moved Hospital Costs
The problem may not be the investment. It may be the target of the intervention.
More Medications, Less Clarity: Strengthening Polypharmacy Support for CKD Patients
Interdisciplinary coordination between nephrologists, primary care providers, pharmacists, dieticians, and everyone who interacts with patients is essential to ensure patient education, improve adherence, and reduce medication errors.
presented by
From Blind Spots to Better Outcomes: How SNF Data Transparency Strengthens LTSS
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.
Closing the CKD Care Gap with Value-Based Care Models
VBC models deliver significant benefits for CKD management by coordinating medical, behavioral, and social support through multidisciplinary teams. This approach enables providers to personalize care, address barriers to access, and use data-driven strategies to identify and prioritize high-risk patients.
Meeting Patients Where They Are: The Value of Innovation & Collaboration in Expanding Kidney Care Access
This requires leveraging technology and partnerships in new ways to break down traditional barriers, designing therapies to fit more seamlessly into patients’ lives, and creating more equitable access to life-sustaining treatments.
Maze Therapeutics Drug Shows Potential to Top Asset Acquired by Otsuka for $800M
With positive Phase 1 results for the metabolic disorder drug MZE782, Maze Therapeutics plans to advance the small molecule to Phase 2 tests in phenylketonuria and chronic kidney disease. Following the data readout, Maze raised $150 million in a private placement.
From Fee-for-Service to Value-Based Care: Enhancing Outcomes in Nephrology
A systemic change from FFS to VBC would represent more than a payment model switch, but rather a holistic transition toward patient-centered healthcare that prioritizes outcomes over activity.
presented by
Closing the Quality-Affordability Gap in Workplace Mental Health
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
AstraZeneca Secures China Rights to Anemia Drug, Buying FibroGen Unit in $160M Deal
FibroGen secured regulatory approvals for roxadustat in China and Europe, but the FDA rejected the drug and asked for another clinical trial. By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially resuming development of roxadustat in another indication.
Prioritizing CKD Screening Guidelines is Imperative to Combat Global Health Crisis
The consequences for not prioritizing new guidelines for CKD screening have a devastating impact on population health by increasing the global mortality rate and driving higher healthcare costs.
New FDA Approval Adds Chronic Kidney Disease to Ozempic’s Label
Novo Nordisk’s type 2 diabetes drug Ozempic has expanded its label to include chronic kidney disease. The new FDA approval comes as makers of GLP-1 drugs work to expand the uses of these products.
Disrupting Trajectory of Chronic Kidney Disease Mortality Rates Through Digital Health Platforms
Digital solutions are changing the way CKD is managed. Through enhanced connectivity and personalized care plans tailored to individual patient needs, digital technologies allow patients to take proactive steps in managing CKD.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
One Conversation Could Be All It Takes to Identify Chronic Kidney Disease
No one should ever learn about CKD after their kidneys have already failed.
Novo Nordisk Drug Fails Pivotal Test in Hypertension and Chronic Kidney Disease
The Phase 3 results for ocedurenone come less than nine months after Novo Nordisk acquired the drug from KBP Biosciences. Novo Nordisk has stopped the clinical trial in uncontrolled hypertension and chronic kidney disease, but is evaluating potential applications of the small molecule in other indications.
With All the Organ Donation Scrutiny, Ask: What Can We Do to Reduce the Need?
People do not have to die waiting for a kidney. A VBC approach can lead to earlier identification of kidney disease and better management in its earlier stages.
Akebia Recovers From Rejection to Win FDA Approval for Anemia Drug
Approval of Akebia Therapeutics’ Vafseo is based on additional post-marketing safety data from Japan, where the drug has been used since 2020. The FDA rejected the drug two years ago due to concerns about cardiovascular safety.
New Novo Nordisk Ozempic Data Build Case for Adding Kidney Disease to Label
Blockbuster Novo Nordisk drug Ozempic now has clinical trial results showing statistically significant reductions in the risk of kidney disease progression. The company said these results support the expansion of the drug’s label to chronic kidney disease.